The Early Clinical Trial Unit (ECTU) at the National Center for Tumor Diseases (NCT/UCC) in Dresden has initiated a clinical study testing the cancer immunotherapy IMA401 in patients with advanced solid tumors. IMA401 is a bispecific T-cell engager (TCER) designed to target specific antigens on cancer cells.
The study, which began in 2024, aims to evaluate the safety and preliminary efficacy of IMA401. According to the NCT/UCC Dresden, the therapy is administered intravenously and is intended to activate the patient's own immune system to attack tumor cells.
As of June 2026, the trial is ongoing, and no results have been published. The ECTU specializes in early-phase clinical trials for innovative cancer therapies.
